Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
/Free Sign Up
 Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Breaking News

U.S. Stocks Surge at the Open as Tech Leads Latest Rally

ADMA Biologics Inc (ADMA)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow ADMA Biologics Inc's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
1.9450 +0.0750    +4.01%
10:08:31 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
ISIN:  US0008991046 
CUSIP:  000899104
  • Volume: 296,343
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 1.8800 - 1.9700
ADMA Biologics Inc 1.9450 +0.0750 +4.01%

ADMA Biologics Inc Company Profile

 
Get an in-depth profile of ADMA Biologics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology
SectorHealthcare
Employees

407

Equity Type

ORD

ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include ADMA BioManufacturing and Plasma Collection Centers. The Company’s ADMA BioManufacturing segment reflects its immune globulin manufacturing and development operations in Florida. The Plasma Collection Centers segment consists of approximately three plasma collection facilities. Its products include BIVIGAM, ASCENIV and Nabi-HB. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons.

Contact Information

Address 465 State Route 17
Ramsey, 07446
United States
Phone 201 478 5552
Fax 201 478 5553
Web www.admabiologics.com

Top Executives

Name Age Since Title
Adam S. Grossman 44 2007 Co-Founder, President, CEO & Director
Jerrold B. Grossman 73 2007 Co-Founder & Vice Chairman of the Board
Bryant E. Fong 48 2012 Independent Director
Lawrence P. Guiheen 70 2012 Independent Director
Martha J. Demski 68 2020 Independent Director
Roy F. Chemaly - 2014 Member of Scientific Advisory Board
Steven Arnote Elms 58 2007 Independent Chairman
Jordan S. Orange - 2014 Member of Scientific Advisory Board
Jean-Laurent Casanova - - Member of Scientific Advisory Board
E. Richard Stiehm - 2014 Member of Scientific Advisory Board
Erwin W. Gelfand - - Member of Scientific Advisory Board
Michael G. Ison - 2020 Member of The Scientific Advisory Board
Young T. Kwon 50 2021 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

ADMA Comments

Write your thoughts about ADMA Biologics Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Mario Fe
Mario Fe Nov 11, 2021 5:20AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
https://www.admabiologics.com/investors/press-releases/detail/521/adma-biologics-reports-record-third-quarter-2021-financial
Reply
3 0
Report
Feed Seow
Feed Seow Sep 09, 2021 10:54AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Where is ADMA headed with FDA, down or up?
Reply
0 0
Report
Mr Feesher
Mr Feesher Sep 09, 2021 10:54AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I feel $2.79 resistance then ath by december or feb 22
Reply
0 0
Report
Mario Fe
Mario Fe Aug 11, 2021 4:20PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
https://finance.yahoo.com/news/adma-biologics-reports-record-second-200500104.html
Reply
4 0
Report
Riccardo Sandokan
Riccardo Sandokan May 03, 2021 8:15AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
03/05/2021 13:01 - RSFU.S. RESEARCH ROUNDUP-Federated Hermes, Fidelity National Financial, JetBlue AirwaysMay 3 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Federated Hermes, Fidelity National Financial and JetBlue Airways, on Monday.....................Adma Biologics Inc : H.C. Wainwright cuts target price to $10 from $11
Reply
7 1
Report
Mke Gee
Mke Gee Apr 28, 2021 10:13AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Gaureentee $5 Very Sooon!!! 💰 FDA approval!
Reply
8 1
Report
Baichen Zhang
Baichen Zhang Mar 26, 2021 7:29PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
If you draw anything on its monthly chart, it's going to be a penny stock soon. GLTA
Reply
1 3
Report
Baichen Zhang
Baichen Zhang Mar 26, 2021 5:35PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Skip7 hours ago I see a lot of people asking how this stock can go down on what seems to be good progress on the revenue and expansion front. Do your homework. Post
Reply
1 1
Report
Baichen Zhang
Baichen Zhang Mar 26, 2021 5:35PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
ADMA is suffering from continued and persistent dilution. Read the terms of the Open Market Sale Agreement with Jefferies and the terms of the credit arrangement with Perceptive. ADMA had negative cash flow of over $100MM in 2020 and they owe Perceptive Advisors $100MM + interest.
Reply
0 0
Report
Baichen Zhang
Baichen Zhang Mar 26, 2021 5:35PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
With the issuance last year (Feb '20 offering) of 27MM common shares combined with the total open market agreement sales (Jefferies) in 2020 of an additional 18.5MM shares plus the 2021 year to date issuance of 16MM shares (Jefferies), this company is dangerously close to maxing out its authorized common shares of 150MM.
Reply
0 0
Report
Baichen Zhang
Baichen Zhang Mar 26, 2021 5:35PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
If they have to seek approval from shareholders to authorize more common shares, or issue "blank check" preferred with no shareholder vote required...dilution will continue to keep this stock headed down...so don't count on any "short squeeze" as a rescue to your long position. I don't have anything negative to say about ADMA's business or management; you just need to look at the capital structure and understand the forces that may be working against you on the long side. Stay safe, be well.
Reply
0 1
Report
Baichen Zhang
Baichen Zhang Mar 26, 2021 5:35PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Just posted above comments from yahoo ADMA board, and I totally agree with above honest opinions.
Reply
0 0
Report
Baichen Zhang
Baichen Zhang Mar 26, 2021 5:18PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
what? diluted more?! Grossman is insane! we could see it going to $1 soon
Reply
0 0
Report
Baichen Zhang
Baichen Zhang Mar 26, 2021 5:18PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
If it is below $1 and stays, would be pleased to see the reverse split...10X, or 20X... Good luck everyone on the boat!
Reply
0 0
Report
Baichen Zhang
Baichen Zhang Mar 26, 2021 5:18PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Anyone can tell if Raymond James PT $6 is the price after reverse-split, or not?
Reply
0 0
Report
Сергей Дмитриев
Сергей Дмитриев Mar 25, 2021 5:34PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Executed Commercially with Significant Year-Over-Year Revenue Growth. Achieved full year 2020 total revenues of $42.2 million, compared to $29.3 million for the full year 2019, reflecting a substantial 44% increase. Achieved fourth quarter 2020 total revenues of $14.0 million, compared to $12.0 million for the fourth quarter of 2019, representing an approximately 16% increase.
Reply
0 1
Report
Baichen Zhang
Baichen Zhang Mar 24, 2021 5:44PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
double down at 1.85 1.5 and $1
Reply
0 0
Report
Baichen Zhang
Baichen Zhang Mar 24, 2021 5:44PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
double-down no more, will exit from time to time
Reply
1 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email